The efficacy of Ezetimibe added to ongoing Fibrate-Statin therapy on postprandial lipid profile in the patients with type 2 Diabetes mellitus

Journal of Diabetes & Metabolic Disorders

Zahra Shajari²  Saeideh Mazloomzadeh³  Nima Hojeghani¹  Faranak Sharifi³ 

[1] Department of Internal Medicine, Vali asr Hospital, Zanjan, Iran;Zanjan Metabolic Diseases Research Centre, Vali-e-asr Hospital, Zanjan, Iran;Metabolic Diseases Research Centre, Zanjan University of Medical Sciences, Zanjan, Iran

关键词: Type 2 diabetes;    Postprandial hypertriglyceridemia;    Gemfibrozil;    Ezetimibe;   

Others  :  807008
DOI  :  10.1186/2251-6581-12-24

 received in 2012-10-20, accepted in 2013-05-27,  发布年份 2013

【 摘 要 】

Background

Postprandial hypertriglyceridemia in diabetes mellitus can be followed by endothelial dysfunction, impaired vascular compliance and increased cardiovascular complications. So focus on better control of postprandial hypertriglyceridemia is as important as controlling fasting triglyceride level in type 2 DM.

Objective

We evaluated the effect of ezetimibe adding to fibrate or statin on postprandial hypertriglyceridemia.

Methods

In a randomized controlled clinical trial, 47 subjects with type 2 diabetes and hypertiglyceridemia were enrolled and divided in three treatment groups including Gemfibrozil 1200_mg/d + placebo(group A), Ezetimibe10_mg/d + Gemfibrozile 1200_mg/d(group B) or Ezetimibe10_mg/d + Atorvastatin10_mg/d (group C) for a 6- week period. Oral fat loading test were performed in the initiation and also at the end of the study and lipid profile and APO_B were measured.

Results

Fasting and postprandial serum triglyceride (TG) decreased significantly with all the three treatment groups with no difference between them in the percent of TG reduction. Although serum total cholesterol decreased significantly in all the three groups of treatment its reduction was more prominent in group C(−38.1% ± 11.2%in group C vs. -16.5% ± 19.6% and −7.2% ± 10.7% in groups B & A respectively, p < 0.0001 ). Fasting serum HDL increased significantly only by Gemfibrozil (23.4% ± 28.4% vs. 6.4% ± 18.9% and 1.8% ± 17.7%, p < 0.05 ). Fasting serum APO_B was reduced only in ezetimibe containing groups (B &C).

Conclusion

Adding ezetimibe to gemfibrozil has no additional effect on reducing postprandial TG but ezetimibe can potentiate the effect of low-dose atorvastatin on lowering TG and LDL-c.

【 授权许可】

   
2013 Sharifi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hyson D, Rutledge JC, Berglund L: Postprandial lipemia and cardiovascular disease. Curr Atheroscler Rep 2003, 5:437-444.
• [2]Carmena R: Type 2 diabetes, dyslipidemia, and vascular risk: Rationale and evidence for correcting the lipid imbalance. Am Heart J 2005, 150:859-870.
• [3]Steiner G: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes, the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001, 10(357):905.
• [4]Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides A, Mahmood S, Richmond W, Mather H, Sharp P, Feher M: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998, 21:641-648.
• [5]Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, Mellars L, Maxwell SE, Patrick JE, Cutler D, Batra VK, Melton B, Affrime MB: Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmaco 2002, 54:309-319.
• [6]Farnier M, Massimo Volpe M, Massaad R, Davies MJ, Allen C: Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005, 102:327-332.
• [7]Bozzetto L, Annuzzi G, DellaCorte G, Patti L, Cipriano P, Mangione A, Riccardi G, Rivellese A: Ezetimibe beneficiallyinfluencesfastingandpostprandialtriglyceride-rich lipoproteins intype2diabetes. Atherosclerosis 2011, 217:142-148.
• [8]IPAQ. Short last 7 days self-administered. The international physical activity questionnaire. http://www.ipaq.ki.se webcite
• [9]Harano Y, Miyawaki T, Nabiki J: Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. Endocr J 2006, 53:173-180.
• [10]Koskinen P, Manttari M, Manninen V: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820-825.
• [11]Stein EA: An investigative look: selective cholesterol absorption inhibitors: embarking on a new standard of care. Am J Manag Care 2002, 8:36-39.
• [12]Kronenberg HM, Melmed S: Williams text book of endocrinology. 11th edition. United Stated of America: Saunders Elsevier press; 2008.
• [13]Nutescu EA, Shapiro NL: Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy 2003, 23:1463-1474.
• [14]Uemura Y, Watarai M, Ishii H, Koyasu M, Takemoto K, Yoshikawa D, Shibata R, Tatsuaki M: Atorvastatin 10 mg plus ezetimibe 10 mg compared with atorvastatin 20 mg: Impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol 2012, 59:50-56.
• [15]Masuda D, Nakagawa-Toyama Y, Nakatani K: Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009, 39:689-698.
• [16]Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M: Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007, 14:45-50.
• [17]Olijheck JK, Hajer GR, Yolanda G, Dallinga-Thie G, Visseren F: The effects of low-dose Simvastatin and Ezetimibe compared to high-dose Simvastatin alone on post-fat load endothelial function in patient with metabolic syndrome. J Cardiovasc Pharmacol 2008, 52:145-150.
• [18]Nakamura T, Hirano M, Kitta Y, Fujioka D, Saito Y, Kawabata K, Obata J, Watanabe Y, Watanabe K, Kugiyama K: A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J Cardiol 2012, 60:12-17.
• [19]Rosenson RS, Wolff DA, Huskin AL, Helenowski IB I, Rademaker AW: Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertrigelyceridemia and the metabolic syndrome. Diabetes Care 2007, 30:1945-1951.
• [20]Feldman T, Koren M, Insull W Jr, McKenney J, Schrott H, Lewin A: Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004, 93:1481-1486.
• [21]Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A: Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003, 91:418-424.
• [22]Karpe F: Postprandial lipemia—effect of lipid-lowering drugs. Atheroscler Suppl 2002, 3:41-46.
• [23]Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002, 106:1211-1218.
• [24]Curtin A, Deegan P, Owens D, Collins P, Johnson A, Tomkin GH: Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Acta Diabetol 1996, 33:205-210.
• [25]Annuzzi G, Giacco R, Patti L: Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance. Nutr Metab Cardiovasc Dis 2008, 18:531-538.
• [26]Yuan G, Al-Shali KZ, Hegele RA: Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007, 176:1113-1120.
• [27]Rosenson RS: Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 2008, 6:1319-1330.
• [28]Marchesi S, Lupatteli G, Lombardini R, Roscini AR, Siepi D, Vaudo G, Pirro M, Sinzinger H, Schillaci G, Mannarino E: Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia. J Clin Phar Therap 2003, 28:419-424.
• [29]Farnier M: Pharmacotherapy of mixed hyperlipidemia with Ezetimibe-Fenofibrate combination therapy. Clinical Medicine:Therapeutics 2009, 1:1703-1713.
• [30]Masana L, Mata P, Gagne C, Sirah W, Cho M, Johnson-Levonas AO: Long-term safety and, tolerability profiles andlipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: A multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin Ther 2005, 27:174-184.
• [31]Ballantyne CM, Lipka LJ, Sager PT, Strony J, Alizadeh J, Suresh R: Long-term safety and tolerability profile of ezetimibe and atorvastatin co-administration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract 2004, 58:653-658.